DFX Intelligence
Family Office Intelligence
A continuously maintained graph of U.S. family offices: identity, team, observed investments, public holdings, relationships and dated signals of change. Facts, inferences and estimates are labelled as such, with the source and the date, on every row. Unknown is printed as unknown.
Family office profile
Dolby Family Ventures LLC
San Francisco, CAFamily investment companyidentity confidence 80%Top 500 by research prioritydolbyventures.com
Why this class: Dolby Family Ventures is the Dolby family's venture investment vehicle, formed in honor of Ray Dolby, investing family capital in early-stage science and technology companies..
Verified Sep 13, 2026 (5 days ago)
Last observed Sep 14, 2026 · 66 observations · 3 sources
24 people · 76 investments · 0 public positions · 16 events
Identity
80
high
Data depth
80
high
Freshness
100
high
Active deployment
25
moderate
Direct investing
85
high
External managers
0
low
Private markets
80
high
Sponsor-friendly
0
low
Real estate
0
low
Co-investment
100
high
Contactability
90
high
Mandate confidence
90
high
Twelve separate dimensions, each 0 to 100 from listed components. There is no single family office score; the components are in the evidence section.
Overview
Profile completeness 72% (high value, high value deep; the most valuable missing fact is fund relationships)
identityclassificationwealth origincapital-scale evidencepeoplecontactsmandatedirect investmentsfund relationshipsco-investorssponsor relationshipsreal estatepublic holdingsrecent eventsprovenancefreshness
- Classification
- Family investment company
- Description
- Investing in early-stage companies solving the biggest science and engineering challenges since 2014.
- Headquarters
- San Francisco, CA
- Office address
- 999 BRANNAN STREET, PENTHOUSE SUITE, San Francisco, CA, 94103
- Business phone
- 415-449-1005
- Website
- dolbyventures.com
- Year established
- unknown
- Assets under management
- unknown
- Foundation assets (IRS)
- $83.8M across 1 related private foundation, per the IRS master file; the foundation's assets, not the office'sFact
- Capital scale
- Reported office AUM: unknown. Related foundation assets $83.8M. These are different facts and are never added together.
- SEC registration
- ERA since Jul 12, 2021Fact
- Private funds advised
- 2 (PE n/a, VC 2, hedge n/a, real estate n/a), gross assets $104MFact
Classification history
- Sep 13, 2026Family investment company 80%Dolby Family Ventures is the Dolby family's venture investment vehicle, formed in honor of Ray Dolby, investing family capital in early-stage science and technology companies.Factverifieddolbyventures.com“In honor of Ray Dolby, our Fund formalizes the Dolby family”
- Sep 13, 2026Single family office (probable) 70%registered adviser whose private funds are 99.0% owned by itself and its related persons ($136M gross): proprietary capital, not clients' moneyInference
- Sep 12, 2026Candidate 45%registered adviser with a family-named firm (investments, holdings, capital, wealth)Inference
Family and wealth origin
- Family served
- Dolby family (heirs of Ray Dolby, founder of Dolby Laboratories)
- Source of wealth
- Dolby Laboratories (audio technology) founded by Ray Dolby; family trusts hold Class B control stock
- Operating company origin
- Dolby Laboratories, Inc. (NYSE: DLB); Dagmar Dolby beneficially owns 99.8% of Class B
Team
| Person | Title | Responsibility | Business contact | Source |
|---|---|---|---|---|
| David Dolby family | Founder and CEO | Family principal · investment decisions | email: dave@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Alona Cochran | Office Manager & Executive Assistant | Leadership | email: alona@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Andrew Krowne | Managing Partner | Leadership | email: andrew@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Andrew Lawrence Krowne | Member | Leadership | email: andrew@dolbyventures.com (verified by provider, Sep 15, 2026) | reports.adviserinfo.sec.gov Fact |
| David Dolby | CEO | Leadership | email: dave@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Mei Liang | Vice President, Finance | Leadership | email: mei@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Pascal Levensohn | Executive Chairman | Leadership | email: pascal@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Pascal Levensohn | Executive Chairman | Leadership · investment decisions | email: pascal@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Reetika Bhardwaj | Principal | Leadership | email: reetika@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Alona Cochran | Office Manager & Executive Assistant | Operations and finance · investment decisions | email: alona@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Mei Liang | Vice President, Finance | Operations and finance · investment decisions | email: mei@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Edward Chang, MD | Scientific Advisory Board | Other · investment decisions | none on record | dolbyventures.com Fact |
| Howard Fillit, MD | Scientific Advisory Board | Other · investment decisions | none on record | dolbyventures.com Fact |
| Husseini Manji, MD | Scientific Advisory Board | Other · investment decisions | none on record | dolbyventures.com Fact |
| Lennart Mucke, MD | Scientific Advisory Board | Other · investment decisions | none on record | dolbyventures.com Fact |
| LIN Ning | Senior Associate | Other | email: lin@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Maurizio Fava, MD | Scientific Advisory Board | Other · investment decisions | none on record | dolbyventures.com Fact |
| Michael Weiner, MD | Scientific Advisory Board | Other · investment decisions | none on record | dolbyventures.com Fact |
| Rudolph E. Tanzi, PhD | Scientific Advisory Board | Other · investment decisions | none on record | dolbyventures.com Fact |
| Usua Amanam, PhD | Senior Associate | Other | email: usua@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Andrew Krowne | Managing Partner | Venture · investment decisions | email: andrew@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| LIN Ning | Senior Associate | Venture · investment decisions | email: lin@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Reetika Bhardwaj | Principal | Venture · investment decisions | email: reetika@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
| Usua Amanam, PhD | Senior Associate | Venture · investment decisions | email: usua@dolbyventures.com (verified by provider, Sep 15, 2026) | dolbyventures.com Fact |
Office contact points
Office address: 999 BRANNAN STREET, PENTHOUSE SUITE, San Francisco, CA, 94103 (published by the subject) adviserinfo.sec.gov
Investment mandate
5 investments on the record; sectors: software, healthcare products
Stated (their words, cited)
No cited statement of mandate on the record.
Observed (from the investment record)
- States
- none Fact
- Control
- unknown (5) Fact
- Sectors
- software (1), healthcare products (1) Fact
- Subsectors
- none Fact
- Co investors
- none Fact
- Asset classes
- none Fact
- Direct vs fund
- Fund: 0 · Direct: 5 · Real estate: 0 Fact
- Sponsors backed
- none Fact
- Investment count
- 5 Fact
- Investment kinds
- portfolio listing (5) Fact
- First and last deal
- Last: unknown · First: unknown Fact
- Lead vs participant
- unknown (5) Fact
- Disclosed check sizes
- Max: unknown · Min: unknown · Count: 0 Factamounts are only what a source disclosed; never backsolved from a round
Inferred (regulatory shape and team)
- Venture funds advised
- 2 InferenceForm ADV Item 7.B
- Invests directly
- About 100 portfolio companies
- Allocates to managers
- unknown
- Asset classes
- Family portfolio overseen by David Dolby spans private equity, venture capital and real estate
- Sectors
- Excludes non-platform oncology, cardiovascular and rare disease
- Geography
- unknown
- Check size
- unknown
Direct investments
| Date | Company | Kind | Sector | Role | Amount | With | Source |
|---|---|---|---|---|---|---|---|
| Mar 13, 2025 | Montara Therapeutics | Round participation | unknown | participant · minority | unknown round $20.0M | Two Bear Capital (co investor), KdT Ventures (co investor) | globenewswire.com Fact “The round, which brings Montara’s total seed funding to $28 million, includes increased participation from all existing investors, including” |
| Jul 30, 2024 | Montara Therapeutics | Round participation | Brain-targeted neuroscience drugs | participant · minority | $8.0M | SV Health Investors Dementia Discovery Fund (co investor), Two Bear Capital (co investor), KdT Ventures (co investor) | montaratx.com Fact “Dolby Family Ventures and KdT Ventures also participated in the round.” |
| n/a exit Nov 1, 2022 | Tempo Automation | Venture | PCB assembly automation | unknown · minority | unknown | Lux Ventures IV (co investor), Point72 Ventures (co investor), Draper Associates (co investor), Industry Ventures Direct (co investor), SoftTech VC (co investor) | sec.gov Fact “Dolby Family Ventures II LP” |
| n/a | Hyperfine (portable MRI) | Venture | Portable MRI | unknown · minority | unknown | GV 2019, L.P. (co investor) | sec.gov Fact “DOLBY FAMILY VENTURES, L.P.” |
| n/a | Cortexyme | Venture | Alzheimer's therapeutics (P. gingivalis) | participant · minority | unknown | Pfizer Ventures (co investor), Takeda Ventures (co investor), Verily Life Sciences (co investor), Sequoia Capital (co investor), Breakout Ventures (co investor), EPIQ Capital Group (co investor), Vulcan Capital Management (co investor) | sec.gov Fact “Breakout Ventures, Dolby Family Ventures, EPIQ Capital Group, the Lamond Family and Vulcan Capital, amongst others.” |
| n/a | Icon Aircraft | Venture | Light sport aircraft | unknown · minority | unknown | none named | dolbyventures.com Fact “Icon Aircraft is redefining the small aircraft experience for pilots of all age and experience levels with the Icon A5 amphibious light spor” |
| n/a | LeoLabs | Venture | LEO tracking | unknown · minority | unknown | none named | dolbyventures.com Fact “LeoLabs is transforming the way satellite operators, commercial enterprises and federal agencies across the world launch and track missions ” |
| n/a | Ubotica | Venture | On-board satellite AI | unknown · minority | unknown | none named | dolbyventures.com Fact “Ubotica on-board AI edge processing transforms satellite services and data processing.” |
| n/a | Atomos Nuclear and Space | Venture | Orbital transfer vehicles | unknown · minority | unknown | none named | dolbyventures.com Fact “Atomos Space is an aerospace company building and developing orbital transfer vehicles.” |
| n/a | Phase Four | Venture | Plasma satellite propulsion | unknown · minority | unknown | none named | dolbyventures.com Fact “Phase Four plasma propulsion systems improve navigation and efficiency for in-orbit satellite missions.” |
| n/a | Ursa Major Technologies | Venture | Rocket propulsion | unknown · minority | unknown | none named | dolbyventures.com Fact “Ursa Major Technologies manufactures propulsion systems for micro- and nano-satellite launch vehicles.” |
| n/a | Regent | Venture | Electric seagliders | unknown · minority | unknown | none named | dolbyventures.com Fact “Regent all-electric Seaglider™ vessel is a wing-in-ground-effect craft to deliver high speed maritime transportation with greater versatilit” |
| n/a | MedCrypt | Venture | Medical device cybersecurity | unknown · minority | unknown | none named | dolbyventures.com Fact “MedCrypt healthcare cybersecurity for medical devices cryptographically secures patient data, monitors device vulnerability and behavior, in” |
| n/a | TripleBlind | Venture | Privacy-enhancing computation | unknown · minority | unknown | none named | dolbyventures.com Fact “TripleBlind enterprise digital privacy as a service enables companies to safely leverage extremely sensitive data and algorithms in encrypte” |
| n/a | DigiLens | Venture | Holographic waveguides | unknown · minority | unknown | none named | dolbyventures.com Fact “DigiLens holographic optical waveguide technology and material science delivers unique optical solutions for display and imaging application” |
| n/a | Mojo Vision | Venture | Micro-LED displays | unknown · minority | unknown | none named | dolbyventures.com Fact “Mojo Vision single backplane high definition RGB micro-LED display technology platform produces ultra-high brightness with high efficiency f” |
| n/a | Chirp Microsystems | Venture | Ultrasonic 3D sensing | unknown · minority | unknown | none named | dolbyventures.com Fact “Chirp Microsystem ultrasonic transceivers generate real-time 3D depth mapping for AR/VR, drones, and Connected Devices.” |
| n/a | AltSpaceVR | Venture | Social VR | unknown · minority | unknown | none named | dolbyventures.com Fact “AltSpaceVR is a virtual reality software company bringing two-dimensional web content into shared virtual spaces and extending the web to cr” |
| n/a | Eargo | Venture | Hearing aids | unknown · minority | unknown | none named | dolbyventures.com Fact “Eargo is an audio hardware company revolutionizing the hearing experience.” |
| n/a | August | Venture | Smart locks | unknown · minority | unknown | none named | dolbyventures.com Fact “August builds products that make life simpler, allowing physical environments to seamlessly respond to user behavior. The August Smart Lock,” |
| n/a | SoundThinking (ShotSpotter) | Venture | Gunfire detection | unknown · minority | unknown | none named | dolbyventures.com Fact “SST ShotSpotter Technology is a gunfire detection system of acoustic sensors and analytics to precisely locate gunfire across urban and rura” |
| n/a | Eyefluence | Venture | Eye-tracking UI for HMDs | unknown · minority | unknown | none named | dolbyventures.com Fact “Eyefluence embedded systems translate intent into action through human eye-driven UI/UX technologies for head mounted displays (HMDs).” |
| n/a | Lightform | Venture | Projected AR tools | unknown · minority | unknown | none named | dolbyventures.com Fact “Lightform creates simple, powerful tools that connect the real and digital worlds through computer vision and projected augmented reality.” |
| n/a | Niantic Labs | Venture | Location-based AR games | unknown · minority | unknown | none named | dolbyventures.com Fact “Niantic Labs is a mobile software company focused on location-based augmented reality games. The company’s first title, Pokémon Go, launched” |
| n/a | Twelve | Venture | CO2 electrochemical conversion | unknown · minority | unknown | none named | dolbyventures.com Fact “Twelve applies electrochemical processes to recycled industrial waste products, starting with CO₂, to efficiently produce useful chemicals a” |
| n/a | Kuprion | Venture | Nanocopper electronics materials | unknown · minority | unknown | none named | dolbyventures.com Fact “Kuprion nanocopper pastes and inks provide higher performance alternatives to lead free solder, AuSn, and NanoSilver for electronic componen” |
| n/a | Diamond Age | Venture | Construction automation | unknown · minority | unknown | none named | dolbyventures.com Fact “Diamond Age full stack software-driven construction automation technology aims to improve quality, speed and cost for building construction.” |
| n/a | Transition Metal Solutions | Venture | Bio-based copper recovery | unknown · minority | unknown | none named | dolbyventures.com Fact “Transition Metal Solutions' data-driven platform delivers site-specific, biologically-targeted solutions that enhance leaching efficiency du” |
| n/a | Soil Action | Venture | Ag-tech soil chemistry sensing | unknown · minority | unknown | none named | dolbyventures.com Fact “Soil Action's sensor and AI-driven platform delivers real-time soil chemistry analysis — on-tractor, in-the-field — transforming variable ra” |
| n/a | Molten Salt Solutions | Venture | Lithium isotope enrichment for nuclear | unknown · minority | unknown | none named | dolbyventures.com Fact “Molten Salt Solutions' novel chromatographic system efficiently separates isotopes in a highly scalable form factor, enabling the production” |
| n/a | Basis Science | Venture | Wearable health tracker | unknown · minority | unknown | none named | dolbyventures.com Fact “Basis Science developed the world’s most advanced wearable health tracker.” |
| n/a | Cytovale | Venture | Sepsis diagnostics device | unknown · minority | unknown | none named | dolbyventures.com Fact “Cytovale is a medical device company that has developed an innovative approach for early detection of sepsis.” |
| n/a | Strateos | Venture | Robotic cloud lab | unknown · minority | unknown | none named | dolbyventures.com Fact “Strateos automates chemistry and biology processes, coupled with tissue analysis, in a closed-loop robotic laboratory to accelerate science ” |
| n/a | goBalto | Venture | Clinical trial startup software | unknown · minority | unknown | none named | dolbyventures.com Fact “goBalto develops next-generation solutions that simplify and accelerate clinical study startup in the pharmaceutical, biotechnology, and med” |
| n/a | Vium | Venture | Preclinical research technology | unknown · minority | unknown | none named | dolbyventures.com Fact “Vium empowers biomedical investigators with technology that accelerates the preclinical drug discovery and development pipeline.” |
| n/a | Zebra Medical Vision | Venture | AI medical imaging | unknown · minority | unknown | none named | dolbyventures.com Fact “Zebra Medical Vision applies computer vision and machine learning to medical imaging.” |
| n/a | Echo Laboratories | Venture | Hybrid microscopes | unknown · minority | unknown | none named | dolbyventures.com Fact “Echo Laboratories has developed table-driven bright field and fluorescent hybrid microscopes” |
| n/a | Numerion Labs (formerly Atomwise) | Venture | AI small-molecule discovery | unknown · minority | unknown | none named | dolbyventures.com Fact “Numerion Labs (formerly known as Atomwise) developed a machine learning-based discovery engine that combines the power of convolutional neur” |
| n/a | Herophilus | Venture | Neurotherapeutics organoid platform | unknown · minority | unknown | none named | dolbyventures.com Fact “Herophilus is a neurotherapeutics platform company that is developing organoid disease models to discover novel drugs for neurological disor” |
| n/a | Switch Therapeutics | Venture | RNAi therapeutics | unknown · minority | unknown | none named | dolbyventures.com Fact “Switch Therapeutics is a biotech company dedicated to revolutionizing RNA interference (RNAi) therapies with conditionally activated siRNAs ” |
| n/a | Iris Medicine | Venture | RNA modality for repeat expansion diseases | unknown · minority | unknown | none named | dolbyventures.com Fact “Iris Medicine develops a new RNA modality to treat diverse patient populations with repeat expansion diseases. Its allele-selective sbRNAs m” |
| n/a | Sensorium Therapeutics | Venture | Mental health therapeutics | unknown · minority | unknown | none named | dolbyventures.com Fact “Sensorium is developing nature-inspired medicines for mental health disorders. Leveraging the proprietary SensAI platform, lead programs pri” |
| n/a | Et Cere | Venture | Depression biotyping | unknown · minority | unknown | none named | dolbyventures.com Fact “Founded by Leanne Williams at Stanford, Et Cere is establishing biotypes for depression with the goal of getting the right treatments to the” |
| n/a | Delix Therapeutics | Venture | Psychiatry (psychoplastogens) | unknown · minority | unknown | none named | dolbyventures.com Fact “Delix Therapeutics is based on the discovery of a novel class of neuroplasticity-promoting therapeutics known as psychoplastogens.” |
| n/a | Cogstate Limited | Venture | Cognitive assessment software | unknown · minority | unknown | none named | dolbyventures.com Fact “Cogstate computerized cognitive assessment technology delivers highly sensitive measures of cognition for clinical trials, healthcare diagno” |
| n/a | Paradromics | Venture | Brain-computer interface | unknown · minority | unknown | none named | dolbyventures.com Fact “Paradromics neural interface technologies will deliver high-volume, bidirectional data streaming capabilities between brains and computers, ” |
| n/a | Salvia BioElectronics | Venture | Neurostimulation for migraine | unknown · minority | unknown | none named | dolbyventures.com Fact “Salvia BioElectronics is developing a minimally invasive neurostimulation therapy for people suffering from chronic migraine.” |
| n/a | Cala Health | Venture | Wearable neuromodulation for tremor | unknown · minority | unknown | none named | dolbyventures.com Fact “Cala is commercializing a FDA-cleared, wearable device that delivers effective therapy for action hand tremor in people with essential tremo” |
| n/a | General Sense (Canaery) | Venture | Neural interface / scent digitization | unknown · minority | unknown | none named | dolbyventures.com Fact “General Sense neural interface technology leverages the superior sense of smell in animal models to detect and digitize the world of scent.” |
| n/a | Bionaut Labs | Venture | Micro-robotic CNS drug delivery | unknown · minority | unknown | none named | dolbyventures.com Fact “Bionaut Labs is developing microscale robots to deliver biologics or small molecule therapies locally to targeted disease areas to help pati” |
| n/a | Magnus Medical | Venture | Neuromodulation for psychiatric disorders | unknown · minority | unknown | none named | dolbyventures.com Fact “Magnus Medical delivers FDA cleared, non-invasive closed-loop neuromodulation technology to effectively treat intractable neurological and p” |
| n/a | Motif Neurotech | Venture | Neuromodulation for mental health | unknown · minority | unknown | none named | dolbyventures.com Fact “Motif Neurotech is pioneering wireless minimally-invasive neuromodulation therapeutics for mental health.” |
| n/a | NeuroBionics | Venture | Endovascular neuromodulation devices | unknown · minority | unknown | none named | dolbyventures.com Fact “NeuroBionics is building the future of precision bioelectronic medicine by developing minimally-invasive devices capable of delivering endov” |
| n/a | MindImmune Therapeutics | Venture | Alzheimer's immunology antibody | unknown · minority | unknown | none named | dolbyventures.com Fact “MindImmune has made a fundamental discovery that implicates the peripheral immune system in the pathology of Alzheimer’s disease and are dev” |
| n/a | PharmatrophiX | Venture | Neurotrophin pathway modulators | unknown · minority | unknown | none named | dolbyventures.com Fact “PharmatrophiX is focused on the development of disease-modifying small molecule drugs, discovering & developing small molecule Neurotrophin ” |
| n/a | Cognition Therapeutics | Venture | Neurodegeneration small molecules | unknown · minority | unknown | none named | dolbyventures.com Fact “Cognition Therapeutics is developing small-molecule therapeutics to address the toxic oligomeric proteins in neurodegenerative diseases” |
| n/a | Athira Pharma | Venture | Regenerative small molecules for neurodegeneration | unknown · minority | unknown | none named | dolbyventures.com Fact “Athira Pharma is a therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant t” |
| n/a | Yumanity Therapeutics | Venture | Neurodegeneration drug discovery | unknown · minority | unknown | none named | dolbyventures.com Fact “Yumanity Therapeutics is taking a new approach to neurodegenerative disease drug discovery and development by correcting the cellular pathol” |
| n/a | Alzeca Biosciences | Venture | Alzheimer's MR imaging agents | unknown · minority | unknown | none named | dolbyventures.com Fact “Alzeca Biosciences develops novel, targeted MR imaging agents for the early detection and diagnosis of Alzheimer's Disease and other neurode” |
| n/a | Tetra Therapeutics | Venture | PDE4 neurology therapeutics | unknown · minority | unknown | none named | dolbyventures.com Fact “Tetra Therapeutics is a clinical stage company developing a platform of pharmaceutical therapies targeting PDE4 enzymes in multiple neurolog” |
| n/a | NeuroTherapia | Venture | Alzheimer's (CB2 microglia) | unknown · minority | unknown | none named | dolbyventures.com Fact “NeuroTherapia is developing new chemical entities targeting CB2 receptors on microglia, significantly reducing the expression of inflammator” |
| n/a | AZTherapies | Venture | Neurology therapeutics | unknown · minority | unknown | none named | dolbyventures.com Fact “AZTherapies is a clinical biopharmaceutical company developing treatments for neurological conditions.” |
| n/a | Therini Bio | Venture | Fibrin-targeted neuro/retinal therapies | unknown · minority | unknown | none named | dolbyventures.com Fact “Therini Bio is a vascular biology company focused on developing novel therapies based on a deep understanding of fibrin and its role in driv” |
| n/a | Enclear Therapies | Venture | Neurodegeneration medical device | unknown · minority | unknown | none named | dolbyventures.com Fact “Enclear Therapies' medical device clears the cerebrospinal fluid of toxic proteins to treat neurodegenerative diseases.” |
| n/a | QurAlis | Venture | ALS/FTD precision therapeutics | unknown · minority | unknown | none named | dolbyventures.com Fact “QurAlis is currently advancing a pipeline with therapeutic candidates that target specific components of neurodegenerative disease pathology” |
| n/a | Cajal Neuroscience | Venture | Neurodegeneration drug discovery | unknown · minority | unknown | none named | dolbyventures.com Fact “Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.” |
| n/a | Cerevance | Venture | CNS therapeutics (NETSseq) | unknown · minority | unknown | none named | dolbyventures.com Fact “Cerevance is a clinical-stage pharmaceutical company that is applying a new technology, called NETSseq, to identify targets and advancing a ” |
| n/a | Libra Therapeutics | Venture | Neurodegeneration (ALS, FTD, AD) | unknown · minority | unknown | none named | dolbyventures.com Fact “Libra Therapeutics is developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative d” |
| n/a | Reservoir Neuroscience | Venture | Dementia therapeutics | unknown · minority | unknown | none named | dolbyventures.com Fact “Reservoir Neuroscience is developing small molecules to restore health to the brain's blood vessels to treat AD and other dementias.” |
| n/a | Monument Biosciences | Venture | Alzheimer's therapeutics | unknown · minority | unknown | none named | dolbyventures.com Fact “Monument Biosciences is developing disease modifying drugs for Alzheimer’s and related dementias anchored in human patient genetics, their r” |
| n/a | Progentos Therapeutics | Venture | Neurodegeneration / multiple sclerosis | unknown · minority | unknown | none named | dolbyventures.com Fact “Progentos Therapeutics is developing pharmaceuticals that stimulate the body's natural repair mechanisms. The lead program targets treatment” |
| n/a | Vandria | Venture | Neurodegeneration / mitophagy inducers | unknown · minority | unknown | none named | dolbyventures.com Fact “Vandria is developing best-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases.” |
| n/a | Developing AI Infrastructure (currently in stealth) | Portfolio listing | unknown | unknown | unknown | none named | dolbyventures.com Fact “listed on https://www.dolbyventures.com/portfolio: Developing AI Infrastructure (currently in stealth) (moove.ai)” |
| n/a | DensityAI Developing AI Infrastructure (currently in stealth) ACTIVE | Portfolio listing | unknown | unknown | unknown | none named | dolbyventures.com Fact “listed on https://www.dolbyventures.com/portfolio: DensityAI Developing AI Infrastructure (currently in stealth) ACTIVE (densityai.com)” |
| n/a | Psychiatry | Portfolio listing | unknown | unknown | unknown | none named | dolbyventures.com Fact “listed on https://www.dolbyventures.com/portfolio: Psychiatry (delixtherapeutics.com)” |
| n/a | Neurotech | Portfolio listing | unknown | unknown | unknown | none named | dolbyventures.com Fact “listed on https://www.dolbyventures.com/portfolio: Neurotech (neurobionics.io)” |
Its own private funds (Form ADV Schedule D 7.B.(1))
Each fund as the office reported it on its own Form ADV. Gross asset value is the fund's assets on the filing date, not a fund size and not capital raised; the related share is what the adviser and its related persons own, which the SEC does not extend to the family's trusts.
| Fund | Type | Gross asset value | Related share | Reported | Form D |
|---|---|---|---|---|---|
| DOLBY FAMILY VENTURES II L.P. | Venture Capital Fund | $104M Mar 19, 2024 | 99% | Jul 12, 2021 to now | |
| DOLBY FAMILY VENTURES L.P. | Venture Capital Fund | $32.2M Mar 19, 2024 | 99% | Jul 12, 2021 to now |
Fund and manager relationships
No fund commitment or manager relationship on the record. Commitment amounts are shown only when public.
Public stakes and holdings
Form 13F holdings
No 13F filing on the record for this office.
Real estate
No documented real estate ownership link. A property is attributed to an office only through a documented control relationship, never from a surname.
Co-investors
| Counterparty | Kind | Shared deals | First, last | Examples | Source |
|---|---|---|---|---|---|
| Two Bear Capital | organisation | 2 | Jul 30, 2024, Mar 13, 2025 | Montara Therapeutics, Montara Therapeutics | montaratx.com |
| KdT Ventures | organisation | 2 | Jul 30, 2024, Mar 13, 2025 | Montara Therapeutics, Montara Therapeutics | montaratx.com |
| SV Health Investors Dementia Discovery Fund | organisation | 1 | Jul 30, 2024 | Montara Therapeutics | montaratx.com |
| Lux Ventures IV | organisation | 1 | undated (historical) | Tempo Automation | sec.gov |
| Sequoia Capital | organisation | 1 | undated (historical) | Cortexyme | sec.gov |
| Vulcan Capital Management | family office | 1 | undated (historical) | Cortexyme | sec.gov |
| Pfizer Ventures | organisation | 1 | undated (historical) | Cortexyme | sec.gov |
| Industry Ventures Direct | organisation | 1 | undated (historical) | Tempo Automation | sec.gov |
| EPIQ Capital Group | family office | 1 | undated (historical) | Cortexyme | sec.gov |
| Takeda Ventures | organisation | 1 | undated (historical) | Cortexyme | sec.gov |
| Breakout Ventures | organisation | 1 | undated (historical) | Cortexyme | sec.gov |
| Draper Associates | organisation | 1 | undated (historical) | Tempo Automation | sec.gov |
| Verily Life Sciences | organisation | 1 | undated (historical) | Cortexyme | sec.gov |
| Point72 Ventures | organisation | 1 | undated (historical) | Tempo Automation | sec.gov |
| GV 2019, L.P. | organisation | 1 | undated (historical) | Hyperfine (portable MRI) | sec.gov |
| SoftTech VC | organisation | 1 | undated (historical) | Tempo Automation | sec.gov |
- KdT Ventures Mar 13, 2025 strong (4) Fact globenewswire.com
- Two Bear Capital Mar 13, 2025 strong (4) Fact globenewswire.com
- KdT Ventures Mar 13, 2025 strong (4) Fact globenewswire.com
- Two Bear Capital Mar 13, 2025 strong (4) Fact globenewswire.com
- SoftTech VC recurring (2) Fact sec.gov
- Industry Ventures Direct recurring (2) Fact sec.gov
- Draper Associates recurring (2) Fact sec.gov
- Point72 Ventures recurring (2) Fact sec.gov
- Lux Ventures IV recurring (2) Fact sec.gov
- SoftTech VC recurring (2) Fact sec.gov
- Industry Ventures Direct recurring (2) Fact sec.gov
- Draper Associates recurring (2) Fact sec.gov
- Point72 Ventures recurring (2) Fact sec.gov
- Lux Ventures IV recurring (2) Fact sec.gov
- GV 2019, L.P. recurring (2) Fact sec.gov
- GV 2019, L.P. recurring (2) Fact sec.gov
- Vulcan Capital Management recurring (2) Fact sec.gov
- EPIQ Capital Group recurring (2) Fact sec.gov
- Breakout Ventures recurring (2) Fact sec.gov
- Sequoia Capital recurring (2) Fact sec.gov
- Verily Life Sciences recurring (2) Fact sec.gov
- Takeda Ventures recurring (2) Fact sec.gov
- Pfizer Ventures recurring (2) Fact sec.gov
- Vulcan Capital Management recurring (2) Fact sec.gov
- EPIQ Capital Group recurring (2) Fact sec.gov
- Breakout Ventures recurring (2) Fact sec.gov
- Sequoia Capital recurring (2) Fact sec.gov
- Verily Life Sciences recurring (2) Fact sec.gov
- Takeda Ventures recurring (2) Fact sec.gov
- Pfizer Ventures recurring (2) Fact sec.gov
- KdT Ventures Jul 30, 2024 strong (4) Fact montaratx.com
- Two Bear Capital Jul 30, 2024 strong (4) Fact montaratx.com
- SV Health Investors Dementia Discovery Fund Jul 30, 2024 recurring (2) Fact montaratx.com
- KdT Ventures Jul 30, 2024 strong (4) Fact montaratx.com
- Two Bear Capital Jul 30, 2024 strong (4) Fact montaratx.com
- SV Health Investors Dementia Discovery Fund Jul 30, 2024 recurring (2) Fact montaratx.com
Independent sponsor relationships
No cited relationship to an independent sponsor.
Signals and timeline
Most significant first: what kind of change it is, its size, whose change it is, and how recent. 16 events. 13F position changes are under Public stakes and holdings.
- Sep 13, 2026Classification changedDolby Family Ventures LLC: PROBABLE_SFO -> FAMILY_INVESTMENT_COMPANY (Dolby Family Ventures is the Dolby family's venture investment vehicle, formed in honor of Ray Dolby, investing family capital in early-stage science and technology companies.)ClassificationFactdolbyventures.com
- Sep 13, 2026Classification changedDolby Family Ventures LLC: CANDIDATE_FAMILY_OFFICE -> PROBABLE_SFO (registered adviser whose private funds are 99.0% owned by itself and its related persons ($136M gross): proprietary capital, not clients' money)ClassificationInferenceno URL
- Sep 11, 2026Office discoveredDolby Family Ventures LLC found on the SEC adviser roster (name)DiscoveryInferenceadviserinfo.sec.gov
- Jul 12, 2021Private fund first reportedDolby Family Ventures LLC first reported DOLBY FAMILY VENTURES II L.P. on Form ADV at $73.2M gross asset valueVehiclesFactadviserinfo.sec.gov
- Jul 12, 2021Private fund first reportedDolby Family Ventures LLC first reported DOLBY FAMILY VENTURES L.P. on Form ADV at $74.2M gross asset valueVehiclesFactadviserinfo.sec.gov
- Mar 11, 2022Fund gross assets upDOLBY FAMILY VENTURES II L.P.: gross asset value $73.2M to $126.2M between the 2021-07-12 and 2022-03-11 filings (+72%)VehiclesFactadviserinfo.sec.gov
- Mar 28, 2023Fund gross assets downDOLBY FAMILY VENTURES II L.P.: gross asset value $126.2M to $86.8M between the 2022-03-11 and 2023-03-28 filings (-31%)VehiclesFactadviserinfo.sec.gov
- Mar 28, 2023Fund gross assets downDOLBY FAMILY VENTURES L.P.: gross asset value $58.0M to $39.0M between the 2022-03-11 and 2023-03-28 filings (-33%)VehiclesFactadviserinfo.sec.gov
- Aug 25, 2026Portfolio add-on acquisitionPortfolio company Ursa Major Technologies to go public via SPACDirect investmentsFactdolbyventures.com
- Jul 30, 2024Direct investmentDolby Family Ventures LLC invested in Montara TherapeuticsDirect investmentsFactmontaratx.com
- Dec 12, 2023Investment team expandedAdds Maurizio Fava, Edward Chang and Husseini Manji to Scientific Advisory BoardPeopleFactdolbyventures.com
- Oct 13, 2023Investment team expandedDolby Family Ventures Team AdditionsPeopleFactdolbyventures.com
- Jun 5, 2023Portfolio add-on acquisitionElement Solutions acquires portfolio company KuprionDirect investmentsFactdolbyventures.com
- Nov 23, 2022Portfolio add-on acquisitionTempo Automation completes SPAC and lists as TMPODirect investmentsFactdolbyventures.com
- Nov 1, 2022Portfolio exitDolby Family Ventures LLC exited Tempo AutomationDirect investmentsFactsec.gov
- Apr 19, 2022Portfolio add-on acquisitionDolby Family Ventures commits to propeller technology (Sharrow Marine)Direct investmentsFactdolbyventures.com
Sources and evidence
Every observation behind this profile: the value, when it was effective, the source, the quote where there is one, and whether it is a fact, an inference or an estimate. 67 shown.
Score components
Freshness
+100 days since the newest source-dated fact or analyst verification (1 days)
Contactability
+40 named decision-makers (Andrew Lawrence Krowne (Member); David Dolby (CEO); Pascal Levensohn (Executive Chairman))
+30 verified business emails (17)
+10 verified business phones (1)
+10 office address
Data confidence
+10 website
+10 description
+10 stated mandate
+10 people
+15 investments
+10 regulatory record
+15 independent sources (3 sources)
Active deployment
+25 dated private investments in last 24 months (Montara Therapeutics (2025-03-13))
Exists confidence
+50 regulatory identifier (CIK, CRD or EIN)
+20 website
+30 independent sources (3 sources)
+30 analyst-verified
Research priority
+10 capital scale (largest of 13F, RAUM, AUM, foundation assets) ($83,766,045)
+15 single family or family investment company
+15 direct investments on record
+4 Form D vehicles linked
+10 deployed in last 24 months
+0 rank (16)
Mandate confidence
+70 mandate supported by observed investments
+20 stated mandate on the record
Identity confidence
+80 classification (FAMILY_INVESTMENT_COMPANY (Dolby Family Ventures is the Dolby family's venture investment vehicle, formed in honor of Ray Dolby, investing family capital in early-stage science and technology companies.))
Real estate propensity
no components; scored 0
Co investment propensity
+80 co-investors on the record (Breakout Ventures; Verily Life Sciences; Vulcan Capital Management; Lux Ventures IV; Pfizer Ventures)
+20 participant in syndicated rounds
Family identity confidence
+60 wealth origin or operating company on the record
+40 family named (Dolby family (heirs of Ray Dolby, founder of Dolby Laboratories))
+20 family principal on staff
Private markets propensity
+60 private markets investments observed
+10 stated venture
+10 Form ADV vc fund count (2.0)
Current activity confidence
+50 dated private investment in 24 months
+25 a source-dated fact within 12 months (1 days)
External manager propensity
no components; scored 0
Direct investment propensity
+70 observed direct investments (76 on the record)
+15 direct investment professional on staff
Independent sponsor propensity
no components; scored 0
| Fact | Value | Effective | Source | Class |
|---|---|---|---|---|
| Form ADV firm type | ERA | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Form ADV admission signal | name | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Form ADV admission signal | name | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Latest Form ADV filing | 2026-03-20 | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Other names (Form ADV 1.B) | Dolby Family Ventures LLC | Sep 11, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Private funds reported (latest Form ADV) | 2 | Mar 19, 2024 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Gross assets of its private funds | $136M | Mar 19, 2024 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Share of its funds owned by itself and related persons | Y | Mar 19, 2024 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Inference |
| Form ADV status | ERA - Active | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| SEC status effective | 2021-07-12 | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Asset allocation stated | Double bottom line: judges portfolio on societal and financial impact “We judge our portfolio companies and our own work in terms of both societal impact and financial impact.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Asset classes | Family portfolio overseen by David Dolby spans private equity, venture capital and real estate “David oversees a portfolio of family investments across a wide range of asset classes that include private equity, venture capital and real estate.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Board participation | Typically takes a fiduciary (board) or observer seat initially “Our support of innovative management teams is not constrained by formal board participation over time, though we typically have a fiduciary or observer position initially.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Branch offices | 1 | Sep 11, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Business phone | 415-449-1005 | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Co invest behavior | Only invests alongside strong syndicate partners “We only invest in companies in conjunction with strong investment syndicate partners.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Decision rights | Dolby Family Ventures LLC is the adviser brand entity (CRD 313994) whose funds are the earlier DFV LP and DFV II LP vehicles; newer vehicles sit with sibling Dolby Family Capital Management LLC “Dolby Family Ventures II LP” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) sec.gov | Inference |
| Description | Investing in early-stage companies solving the biggest science and engineering challenges since 2014. | Sep 14, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Description | Single-family office VC firm structured like a traditional venture fund “David Dolby & Andrew Krowne of Dolby Family Ventures discuss how and why they structured their single-family office VC firm to operate like a traditional venture fund, rather than a typical family off” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) vcmastermind.com | Fact |
| Description | Unaffiliated with Dolby Laboratories and its capital “No, Dolby Family Ventures is unaffiliated with Dolby Laboratories and the company’s capital.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Description | Investing in early-stage companies solving the biggest science and engineering challenges since 2014. | Sep 11, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| External consultant | Scientific Advisory Board evaluates early-stage life science opportunities (Weiner, Tanzi, Mucke, Manji, Fillit, Fava, Chang) “SAB members provide scientific evaluation of early stage investment opportunities, with a focus on disease modifying therapeutics.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Family generation | Second generation: David Dolby (son of Ray Dolby) runs the venture program; described as multi-generational commitment “Under Ray Dolby’s mentorship, David has developed a strong skill set to identify tough problems worth solving and ways to change the world through technology and media.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Inference |
| Family involvement | David Dolby, family member, is CEO; Dagmar Dolby and David share voting power over family trusts' Dolby Labs stock “CEO, Dolby Family Ventures” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) sec.gov | Fact |
| Family served | Dolby family | n/a | DFX model output (classification rules, scores, mandates, matches) no URL | Inference |
| Family served | Dolby family | n/a | DFX model output (classification rules, scores, mandates, matches) no URL | Inference |
| Family served | Dolby family (heirs of Ray Dolby, founder of Dolby Laboratories) “In honor of Ray Dolby, our Fund formalizes the Dolby family’s multi-generational commitment to supporting visionary entrepreneurs and solving big, societal problems.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Formation year | 2014 (fund launched June 2014; family direct tech investing advised from 2012, began 2010) “is founder and Chief Executive Officer of Dolby Family Ventures, an early-stage venture firm unrelated to Dolby Laboratories that launched in June 2014 to invest in companies and technologies with the” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) sec.gov | Fact |
| Headquarters | San Francisco, CA | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Invests directly | About 100 portfolio companies “Over this time, Dolby Family Ventures has invested in about 100 companies across these sectors.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) montaratx.com | Fact |
| Legal entity | Dolby Family Ventures, L.P. (fund vehicle; signatory holder in Hyperfine de-SPAC) “DOLBY FAMILY VENTURES, L.P.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) sec.gov | Fact |
| Legal entity | Dolby Family Ventures II LP (fund vehicle; Tempo Automation stockholder) “Dolby Family Ventures II LP” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) sec.gov | Fact |
| Legal form | Limited Liability Company | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Office address | 999 BRANNAN STREET, PENTHOUSE SUITE, San Francisco, CA, 94103 | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Office type (stated) | family_investment_company “In honor of Ray Dolby, our Fund formalizes the Dolby family” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Operating company origin | Dolby Laboratories, Inc. (NYSE: DLB); Dagmar Dolby beneficially owns 99.8% of Class B “David Dolby is the Special Trustee of the Marital Trust.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) sec.gov | Fact |
| Operating model outsourced | Executive Chairman Pascal Levensohn's Levensohn Venture Partners advised the family's direct tech portfolio from 2012 before the fund launched “Pascal joined Dolby Family Ventures in 2014 after advising the Dolby family on its direct technology investment portfolio since 2012.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Philanthropy program | Ray and Dagmar Dolby Family Fund (David Dolby is CFO) “David is also the CFO of the Ray and Dagmar Dolby Family Fund, supporting a variety of not-for-profit initiatives in academic and research institutions, and other social impact sectors.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Portfolio listed | DensityAI Developing AI Infrastructure (currently in stealth) ACTIVE | Sep 12, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Portfolio listed | Neurotech | Sep 12, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Portfolio listed | Psychiatry | Sep 12, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Portfolio listed | Site by Bunsen | Sep 12, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Portfolio listed | Developing AI Infrastructure (currently in stealth) | Sep 12, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Portfolio page url | https://www.dolbyventures.com/portfolio | Sep 14, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Portfolio page url | https://www.dolbyventures.com/portfolio | Sep 12, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Private funds advised | 2 | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Private fund gross assets | $104M | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Real estate strategy | Dolby family entities own real estate leased to Dolby Laboratories (Burbank 51% family; Wootton Bassett UK 90% family) “We lease our 3601 W. Alameda Avenue, Burbank, California offices from Dolby Properties Burbank, LLC.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) sec.gov | Fact |
| Schedule a rows | 1 | Sep 11, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) reports.adviserinfo.sec.gov | Fact |
| Sectors | Precision neuroscience (Alzheimer's, depression, neurotech), life sciences platforms, aerospace, climate tech, digital deep tech “We fund visionary entrepreneurs solving difficult, long-term problems across precision neuroscience, life sciences platforms, aerospace, digital deep tech, and climate tech.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Sectors | Excludes non-platform oncology, cardiovascular and rare disease “At this time, we do not invest in non-platform companies in oncology, cardiovascular, or rare diseases.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Site mentions | co_investment | Sep 14, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Site mentions | co_investment | Sep 11, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Stage preference | Pre-seed, seed and Series A first checks; follow-ons across lifecycle “Since our founding in 2014, we’ve prioritized early stage investments at the preseed, seed and Series A stage, and often make follow-on investments across a portfolio company’s lifecycle.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Team page url | https://www.dolbyventures.com/people | Sep 16, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Team page url | https://www.dolbyventures.com/people | Sep 14, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Team page url | https://www.dolbyventures.com/people | Sep 12, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Team page url | https://www.dolbyventures.com/people | Sep 11, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Team size total | 9 team members listed on People page (plus 7-person SAB) “Across a decade of investing, Dolby Family Ventures has built a committed team of venture professionals with deep experience as investors, founders, scientists, and engineers.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Estimate |
| Venture funds | 2 | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Source of wealth | Dolby Laboratories (audio technology) founded by Ray Dolby; family trusts hold Class B control stock “They share the founding story of Dolby Family Ventures, which began in 2010 as a way to diversify the family's investments beyond Dolby Laboratories.” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) vcmastermind.com | Fact |
| Website | dolbyventures.com “office website dolbyventures.com” | Sep 13, 2026 | DFX analyst research (General-assisted, every claim URL-cited) dolbyventures.com | Fact |
| Website | dolbyventures.com | Mar 20, 2026 | SEC Form ADV monthly roster (RIA + exempt reporting advisers) adviserinfo.sec.gov | Fact |
| Website read | site-fo-3 | Sep 14, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Website read | site-fo-3 | Sep 12, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Website title | Dolby Family Ventures | Sep 14, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |
| Website title | Dolby Family Ventures | Sep 11, 2026 | Family office and investment company websites (about, team, portfolio, news pages) dolbyventures.com | Fact |